Skip to main content

Shawver Laura's Form 4 filing

ARS Pharmaceuticals, Inc. (SPRY) · filed Apr 8, 2025

Accession no.
0001415889-25-010395
Filed
Apr 8, 2025
Trade date
Apr 7, 2025
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $615.0K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Shawver LauraCIK 0001551891Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 7, 2025Common StockMOption exerciseAcquired+22,509$4.85+$109,168.65232,855Direct
Apr 7, 2025Common StockMOption exerciseAcquired+27,493$4.85+$133,341.05260,348Direct
Apr 7, 2025Common StockSSaleDisposed−50,002$12.30−$615,024.6210,346Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 7, 2025Common StockMOption exerciseDisposed−22,509$0.00$051,555Direct
Apr 7, 2025Common StockMOption exerciseDisposed−27,493$0.00$024,062Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)